Sign In
Buy AB
$36.87
-0.160 (-0.432%)
At Close: Jun 03, 2026
AllianceBernstein (AB) February AUM Down on Unfavorable Markets
01:33pm, Friday, 11'th Mar 2022
AllianceBernstein's (AB) AUM balance for February declines on market depreciation, while net inflows offer some support.
AllianceBernstein AUM declines 1.6% in February
10:30pm, Wednesday, 09'th Mar 2022 Seeking Alpha
AllianceBernstein (AB) preliminary assets under management of $739B at Feb. 28, 2022 fell from $751B at Jan
''Cathie''s a boom or bust investor'' — what Wood''s former boss says about the star fund manager
09:20am, Thursday, 03'rd Mar 2022 MarketWatch
Wood''s former boss at AllianceBernstein says the Ark Invest fund manager "doesn''t disinvest or risk manage"
AB Science annonce le financement de 8,5 millions de dollars US sous forme d’obligations convertibles en actions
07:00am, Monday, 28'th Feb 2022 GlobeNewswire Inc.
NE DOIT PAS ETRE DISTRIBUE OU PUBLIE, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMERIQUE, AU CANADA, EN AUSTRALIE OU AU JAPON
AB Science announces the financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants
07:00am, Monday, 28'th Feb 2022 GlobeNewswire Inc.
NOT FOR DISTRIBUTION, PUBLICATION, RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN
AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications
05:08pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
PRESS RELEASE
AB Science tiendra une conférence virtuelle le 28 février 2022 sur la demande d'enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications
05:08pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
AllianceBernstein Joins Pimco in Turning Cool on Chinas Bonds - BNN Bloomberg
12:43am, Wednesday, 23'rd Feb 2022 BNN Bloomberg
Chinas reluctance to aggressively ease its monetary policy is putting a global bond fund on the defensive.
AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
05:08pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
PRESS RELEASE
AB Science annonce la publication de l’étude clinique pivot de Phase 3 du masitinib dans les formes progressives de la sclérose en plaques dans la revue Neurology® Neuroimmunology & Neuroinflammation
05:08pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
AB Science announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy
04:48pm, Monday, 21'st Feb 2022 GlobeNewswire Inc.
PRESS RELEASE
AllianceBernstein goes ex-dividend tomorrow
03:59pm, Thursday, 17'th Feb 2022 Seeking Alpha
AllianceBernstein (NYSE:AB) had declared $1.29/share quarterly dividend, 44.9% increase from prior dividend of $0.89.Payable March 17; for shareholders of record Feb. 22; ex-div Feb.
AllianceBernstein (AB) January AUM Down on Market Depreciation
05:23pm, Monday, 14'th Feb 2022 Zacks Investment Research
AllianceBernstein's (AB) preliminary AUM for month-end January 2022 of $751 billion is down 3.6% from the previous month. The decline is mainly due to market depreciation.
Has AllianceBernstein (AB) Outpaced Other Finance Stocks This Year?
02:40pm, Monday, 14'th Feb 2022 Zacks Investment Research
Here is how AllianceBernstein (AB) and Assurant (AIZ) have performed compared to their sector so far this year.
